Recent Transactions

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

21-Dec-23
Undisclosed
Australia flag
Target: 

Exit of Homesafe Equity Release Joint Venture

Australia flag
Acquiror: 
Athy Pty Ltd

Adviser to Bendigo and Adelaide Bank on the exit of its investment in the Homesafe Equity Release Joint Venture

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

25-Apr-23
Pending
Undisclosed
United Kingdom flag
Target: 

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

United Kingdom flag
Acquiror: 
Advanz Pharma (UK)

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

22-Aug-22
Pending
$92.9 million
Australia flag
Target: 

Australian Executor Trustees

Australia flag
Acquiror: 
Equity Trustees

Advising Equity Trustees, one of Australia’s leading specialist trustee companies, on the acquisition of Australian Executor Trustees from Insignia Financial

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

29-Jun-21
~$122 million
United Kingdom flag
Target: 

NobleOak Life

United States flag
Acquiror: 
Avant Mutual

Advised Avant Mutual, an Australian member-owned organization providing medical indemnity insurance products to healthcare practitioners, on the exit of its strategic stake in NobleOak Life via IPO

22-Jun-21
Pending
$8.2 billion
Australia flag
Target: 

Milton Corporation

Australia flag
Acquiror: 
Washington H. Soul Pattinson

Adviser to Milton Corporation on its merger with Washington H. Soul Pattinson effected via scheme of arrangement

27-May-21
$1.4 billion
United Kingdom flag
Target: 

Equiniti Group PLC

United States flag
Acquiror: 
Siris Capital Group LLC

Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

29-Dec-20
$110 million
United States flag
Target: 

Biogix, Inc.

United Kingdom flag
Acquiror: 
Alliance Pharma plc

Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc

28-Oct-20
Undisclosed
Australia flag
Target: 

Easton Investments Limited

Australia flag
Acquiror: 
HUB24 Limited

Advising HUB24 Limited (ASX: HUB), a leading specialist investment platform provider, on its proposed acquisition of up to 40% in Easton Investments Limited (ASX: EAS), a leading provider of wealth and accounting solutions. The transaction also included the divestment of HUB24’s subsidiary, Paragem, to Easton

10-Sep-20
$195 million
United Kingdom flag
Target: 

Saga plc

United Kingdom flag
Acquiror: 
Sir Roger De Haan

Advised Sir Roger De Haan on his cornerstone investment of £100mm in Saga, the UK provider of products and services exclusively for the over 50s, as part of its £150m equity raise

01-Jul-20
$225 million
United Kingdom flag
Target: 

Cello Health plc

United States flag
Acquiror: 
Arsenal Capital Partners

Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States

10-Jun-20
$134 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia,  the largest health insurance provider in the Kingdom of Saudi Arabia

02-Mar-20
$NA
United Kingdom flag
Target: 

Global rights (excluding North America) to ThermaCare (United Kingdom)

Italy flag
Acquiror: 
Angelini Pharma

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

20-Feb-20
$NA
United Kingdom flag
Target: 

Asia and US rights to Physiogel

Korea flag
Acquiror: 
LG Household & Health Care

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

28-Oct-19
$NA
Brazil flag
Target: 

Supplier Participações

Brazil flag
Acquiror: 
Totvs

Advised Supplier Participações, the largest credit fintech company in Brazil and the first independent mover in supply chain financing, on the sale of a majority stake to Totvs, the leading provider of management software and related consulting services in Brazil

23-Aug-19
$NA
United Kingdom flag
Target: 

TT International

Japan flag
Acquiror: 
Sumitomo Mitsui Financial Group, Inc.

Advised TT International, a leading independent asset management firm focused on managing high alpha, high conviction active management strategies for institutional investors, on its sale to Sumitomo Mitsui Financial Group, Inc.

19-Jul-19
$NA
Brazil flag
Target: 

Ourinvest DTVM

Brazil flag
Acquiror: 
BTG Pactual

Advised the shareholders of Ourinvest DTVM, a leading Brazilian securities broker focused on providing high net-worth individuals custody, distribution and trading services, on the sale of an 80% stake to BTG Pactual, one of Brazil’s largest independent investment banking firms

Pages

show all